At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients However, the Majority of Surveyed Urologists Have Not Yet Prescribed Xtandi for This Patient Population, According to a New Report from BioTrends Research Group
EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12 months following the U.S. launch of Medivation/Astellas Pharma's Xtandi for docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), the majority of surveyed oncologists stated that they have prescribed Xtandi in clinical practice, whereas the majority of surveyed urologists indicated that they had not yet prescribed Xtandi. Of current non-prescribers who plan on prescribing Xtandi for docetaxel-pretreated mCRPC in the future, the majority of urologists and oncologists stated that they will prescribe Xtandi within the next six months.
The third wave of the LaunchTrends® Xtandi (US) report series—fielded 12 months following the launch of Xtandi for docetaxel-pretreated mCRPC in the United States—finds that surveyed physicians indicated that the lack of steroid requirement and the efficacy profile of Xtandi are among its top perceived advantages compared with Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga, a finding that is consistent with prior waves of research. Nearly one-quarter of surveyed physicians indicated that they perceive no disadvantage of Xtandi compared with Zytiga.
The report also finds that the majority of surveyed physicians stated that first-line use of Zytiga for the treatment of chemotherapy-naive mCRPC remains unchanged following the commercial availability of Xtandi in the docetaxel-pretreated mCRPC setting. According to surveyed oncologists, Zytiga is currently the first-line patient share leader for the treatment of chemotherapy-naive mCRPC and will remain so in six months' time.
"Up to half of surveyed physicians indicated that docetaxel-naive asymptomatic or minimally symptomatic mCRPC and docetaxel-naive symptomatic mCRPC are highly appropriate patient populations for Xtandi," said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc. "If Xtandi is approved for the first-line, asymptomatic or minimally symptomatic mCRPC patient population, surveyed physicians stated that they would prescribe Xtandi to more than 40 percent of their patients in that setting."
LaunchTrends® Xtandi (US) is a three-wave syndicated report series designed to track the uptake of Xtandi following its launch for docetaxel-pretreated mCRPC at one month, six months and 12 months following Xtandi's commercial availability, based upon primary research with U.S. oncologists and urologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. For this third wave of research, BioTrends surveyed 49 U.S. oncologists and 51 U.S. urologists, and conducted qualitative interviews with 10 U.S. oncologists and urologists in October 2013.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE BioTrends Research Group